Company / Accounts Receivable
Summit Therapeutics Inc. Accounts Receivable History
FY2019-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
-
FY2023
5-year range
$0 / $1.5M
FY2019-FY2023
Trend
-100.0%
vs FY2022
Sector context
#114 of 113
Health Care
What the data says
Declined from $1M to $0 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom -1% in Health CareTop 101% of 113
▼
Key checks
Key Insights
- In FY2023, accounts receivable decreased 100.0% year-over-year.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $349.0K | -76.2% |
| FY2021 | $1.5M | +342.3% |
| FY2020 | $331.0K | -38.8% |
| FY2019 | $541.0K | - |
| FY2018 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026